The proposed programs
| AUTOIMMUNITY | ||||
|
Short title |
Evaluated antibodies | Format | Order number | Time period |
| Myasthenia Autoantibodies in myasthenic diseases |
AChR, muscle-specific kinase (MuSK), striated muscles [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1435a-0202 QV 1435a-0204-1 |
2 |
| ANA Autoantibodies against cell nuclei |
Cell nuclei, centromeres, CENP A, CENP B, dsDNA, nucleosomes, ribosomal P protein, RNP/Sm, RNP, Scl-70, Sm, SS-A, SS-B [IgG] | 1 set of specimen 2x400µl | QV 1510-0204 | 1 |
| ANCA Autoantibodies against granulocytes |
ANCA, MPO, PR3 [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1200-0202 QV 1200-0204-1 |
2 |
| CCP Antibodies against CCP |
CCP [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1505-0202 QV 1505-0204-1 |
2 |
| Celiac disease Antibodies against tissue transglutaminase (endomysium) and gliadin |
tTG, EMA, Gliadin [IgA, IgG] |
1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1913-0202 QV 1913-0204-1 |
2 |
| Diabetes Autoantibodies in Diabetes |
GAD, Islet cells, IA2, Zinc transporter 8 [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1020-0202 QV 1020-0204-1 |
2 |
| Kidney Antibodies in autoimmune kidney diseases |
GBM, PLA2R, THSD7A [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1250-0202 QV 1250-0204-1 |
2 |
| Liver Antibodies in autoimmune liver diseases |
AMA, ASMA, F-actin, gp210, LC-1, LKM-1, M2, nuclear dots, nuclear membrane, SLA/LP, Sp100 [IgG, IgAGM] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1300-0202 QV 1300-0204-1 |
1 |
| Myopathies
Antibodies in autoimmune Myopathies
|
cN-1A, EJ, Jo-1, Ku, Mi-2, Mi-2a, Mi-2b, OJ, PL-7, PL-12, PM-Scl, SRP [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1530-0202 QV 1530-0204-1 |
1 |
| Neuronals
Autoantibodies against neuronal antigens
|
Amphiphysin, Aquaporin 4, CASPR2, CV2, GAD, Hu, LGI1, Ma/Ta, MOG, NMDA receptor, Recoverin, Ri, SOX1, Titin, Yo, Zic4 [IgG, IgAGM] |
1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1111-0202 QV 1111-0204-1 |
2 |
| PA
Autoantibodies in pernicious anaemia
|
Intrinsic Faktor, Parietalzellen (PCA) [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1360-0202 QV 1360-0204-1 |
2 |
| Phospholipids
Autoantibodies against phospholipids
|
Cardiolipin [IgG, IgM, IgAGM], ß2-Glykoprotein [IgG, IgM, IgAGM] |
1 set of specimen 2x150µl 2 sets of specimen 2x300µl |
QV 1632-0201 QV 1632-0203-1 |
2 |
| Skin
Autoantibodies against structural proteins of the skin
|
BP 180, BP 230, collagen type VII, desmoglein 1 and 3, desmosomes, epidermal basement membrane [IgG] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 1501-0202 QV 1501-0204-1 |
2 |
| Thyroid gland
Autoantibodies against thyroid gland
|
TG, TPO, TRAk [IgG] |
1 set of specimen 2x300µl 2 sets of specimen 2x600µl |
QV 1010-0203 QV 1010-0206-1 |
2 |
| INFECTIOUS SEROLOGY | ||||
|
Short title |
Evaluated antibodies | Format | Order number | Time period |
| Borrelia
Antibodies against Borrelia burgdorferi sensu lato
|
Borrelia [IgG, IgM], serological diagnosis |
1 set of specimen 2x250µl 2 sets of specimen 2x500µl |
QV 2132-0202 QV 2132-0205-1 |
1 |
| Chikungunya Virus
Antibodies against Chikungunya Virus
|
Chikungunya-Virus [IgG, IgM] |
1 set of specimen 2x300µl 2 sets of specimen 2x600µl |
QV 293a-0203 QV 293a-0206-1 |
3 |
| Dengue Virus
Antibodies against Dengue-Virus
|
Dengue virus [IgG, IgM], Dengue virus NS1 antigen |
1 set of specimen 2x300µl 2 sets of specimen 2x600µl |
QV 266a-0203 QV 266a-0206-1 |
3 |
| EBV
Antibodies against Epstein-Barr Virus
|
EBV-CA [IgG, IgM], EBNA-1 [IgG], avidity, serological diagnosis | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2790-0202 QV 2790-0204-1 |
1 |
| HEV
Antibodies against Hepatitis-E Virus
|
HEV [IgG, IgM, IgAGM] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2525-0202 QV 2525-0204-1 |
1 |
| HSV
Antibodies against Herpes simplex-Virus
|
HSV 1, HSV 2, HSV-1/2 [IgG, IgM] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2531-0202 QV 2531-0204-1 |
1 |
| Measles virus
Antibodies against measles virus
|
Measles vius [IgG, IgM] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2610-0202 QV 2610-0204-1 |
1 |
| Parvovirus B19 Antibodies against Parvovirus B19 |
Parvovirus B 19 [IgG, IgM] | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2580-0202 QV 2580-0204-1 |
1 |
| SARS CoV-2
Antibodies against SARS CoV-2
|
SARS-CoV-2 (NCP), SARS CoV-2 (S1) [IgG], neutralizing antibodies | 1 set of specimen 2x200µl 2 sets of specimen 2x400µl |
QV 2606-0202 QV 2606-0204-1 |
1 |
| Zika virus
Antibodies against Zika virus
|
Zika virus [IgG, IgM, IgA, IgAM] | 1 set of specimen 2x300µl 2 sets of specimen 2x600µl |
QV 2668-0203 QV 2668-0206-1 |
3 |
| ALLERGOLOGY | ||||
|
Short title |
Evaluated antibodies | Format | Order number | Time period |
| Molecular allergology
Molecular Allergology specific IgE
|
Specific IgE (at least 6 different per distribution) | 1 set of specimen 2x1000µl | QV 3002-0210 | 4 |
| Specific IgE
Allergology specific IgE
|
Specific IgE (at least 6 different per distribution) | 1 set of specimen 2x1000µl | QV 3000-0210 | 1 |
| Total IgE
Allergology total IgE
|
Total IgE | 1 set of specimen 2x500µl 2 sets of specimen 2x1000µl |
QV 3840-0205
QV 3840-0210-1
|
1 |
| Deadline for registration/ deregistration | Half-year | Date of shipment | Deadline | |
| Time period 1 | November 30, 2024 June 30, 2025 |
I II |
March 11, 2025 September 9, 2025 |
April 8, 2025 October 7, 2025 |
| Time period 2 | November 30, 2024 June 30, 2025 |
I II |
April 8, 2025 October 14, 2025 |
May 6, 2025 November 11, 2025 |
| Time period 3 | November 30, 2024 | I | March 11, 2025 | April 8, 2025 |
| Time period 4 | June 30, 2025 | II | September 9, 2025 | October 7, 2025 |